By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ADC Therapeutics 

Rue Saint-Pierre 2,

  Lausanne  1003  Switzerland
Phone: 1-212-616-4000 Fax: n/a



Company News
ADC Therapeutics Doses First Patient In Phase I Trial Of ADCT-402 In CD-19 Positive B-cell Non-Hodgkin Lymphomas 3/11/2016 9:32:06 AM
ADC Therapeutics Doses First Patient In Phase I Trial Of ADCT-301 Trial In Acute Myeloid Leukemia 2/9/2016 9:41:26 AM
ADC Therapeutics Announces Positive Pre-clinical Results For Two Of Its Novel Adcs At The American Society of Hematology Conference 12/7/2015 1:49:40 PM
ADC Therapeutics Receives FDA Clearance To Begin Clinical Studies For Its Second Novel Antibody Drug Conjugate ADCT-402 Against Lymphomas And Leukemia 12/4/2015 9:55:02 AM
ADC Therapeutics Announces Expanded Board With Appointment Of Highly Experienced Non-Executive Directors 9/28/2015 11:56:17 AM
ADC Therapeutics Scores $80 Million to Progress Antibody Pipeline 9/2/2015 10:48:09 AM
ADC Therapeutics Appoints Dr. Chris Martin As Chief Executive Officer 6/22/2015 8:39:31 AM
ADC Therapeutics Submits Its First IND For A Novel Antibody Drug Conjugate Against Lymphomas 3/16/2015 11:06:36 AM
ADC Therapeutics Expands Team 9/30/2014 9:45:14 AM
ADC Therapeutics To Move Antibody Drug Conjugate ADCT-401 For Prostate Cancer Into Human Clinical Trials With Partner MedImmune (AZN) 5/19/2014 8:39:39 AM